pSivida Corp. Completes Targeted Enrollment of Phase III Trial of Medidur for Posterior Uveitis

By: via Benzinga
pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.